Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Valneva ( (VALN) ) has shared an update.
On June 25, 2025, Valneva SE announced the successful outcome of its Annual General Meeting, where all resolutions proposed by the Board of Directors were approved. Key decisions included the approval of the 2024 financial statements, authorization for the Board to increase share capital, and the appointment of Dr. Gerd Zettlmeissl to the Board. The company also confirmed its full-year 2025 financial guidance, reinforcing its strategic direction and stability. These developments are expected to strengthen Valneva’s position in the vaccine industry and provide confidence to its stakeholders.
The most recent analyst rating on (VALN) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Valneva stock, see the VALN Stock Forecast page.
Spark’s Take on VALN Stock
According to Spark, TipRanks’ AI Analyst, VALN is a Neutral.
Valneva’s overall stock score reflects financial challenges with persistent losses and negative cash flows, which are the most significant factors. Technical analysis further indicates a bearish trend. Despite strong revenue growth and potential future regulatory successes, the current valuation and profitability concerns weigh heavily on the stock’s attractiveness. The earnings call provides some optimism but is overshadowed by the immediate financial and operational hurdles.
To see Spark’s full report on VALN stock, click here.
More about Valneva
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases, addressing unmet medical needs. The company focuses on providing first-, best-, or only-in-class vaccine solutions and has a strong track record of advancing multiple vaccines from early R&D to approvals. Valneva currently markets three proprietary travel vaccines and is working on vaccine candidates for Lyme disease, Shigella, and Zika virus, among others.
Average Trading Volume: 77,559
Technical Sentiment Signal: Sell
Current Market Cap: $466.7M
For an in-depth examination of VALN stock, go to TipRanks’ Overview page.